Poxviral promoters for improving the immunogenicity of MVA delivered vaccines.
Identifieur interne : 000426 ( Main/Exploration ); précédent : 000425; suivant : 000427Poxviral promoters for improving the immunogenicity of MVA delivered vaccines.
Auteurs : Naif Khalaf Alharbi [Arabie saoudite]Source :
- Human vaccines & immunotherapeutics [ 2164-554X ] ; 2019.
Descripteurs français
- KwdFr :
- Animaux, Anticorps antiviraux, Embryon de poulet, Essais cliniques comme sujet, Humains, Immunogénicité des vaccins, Régions promotrices (génétique), Vaccins antiviraux (génétique), Vaccins antiviraux (immunologie), Vaccins synthétiques (immunologie), Vecteurs génétiques, Virus de la vaccine (génétique), Virus de la vaccine (immunologie).
- MESH :
- génétique : Vaccins antiviraux, Virus de la vaccine.
- immunologie : Vaccins antiviraux, Vaccins synthétiques, Virus de la vaccine.
- Animaux, Anticorps antiviraux, Embryon de poulet, Essais cliniques comme sujet, Humains, Immunogénicité des vaccins, Régions promotrices (génétique), Vecteurs génétiques.
English descriptors
- KwdEn :
- MESH :
- chemical , genetics : Viral Vaccines.
- chemical , immunology : Vaccines, Synthetic, Viral Vaccines.
- chemical : Antibodies, Viral.
- genetics : Vaccinia virus.
- immunology : Vaccinia virus.
- Animals, Chick Embryo, Clinical Trials as Topic, Genetic Vectors, Humans, Immunogenicity, Vaccine, Promoter Regions, Genetic.
Abstract
Modified vaccinia virus Ankara (MVA) is a replication-deficient poxvirus, attenuated in chick embryo fibroblast primary cells. It has been utilised as a viral vector to develop many vaccines against cancer and infectious diseases such as malaria, HIV/AIDS, influenza, and tuberculosis, MERS-CoV, and Ebola virus infection. There is accumulating data from many preclinical and clinical studies that highlights the excellent safety and immunogenicity of MVA. However, due to the complex nature of many pathogens and their pathogenicity, MVA vectored vaccine candidates need to be optimised to improve their immunogenicity. One of the main approaches to improve MVA immunogenicity focuses on optimising poxviral promoters that drive recombinant vaccine antigens, encoded within recombinant MVA vector genome. A number of promoters were described or optimised to improve the development of MVA based vaccines such as p7.5, pF11, and mH5 promoters. This review focuses on poxviral promoters, their optimisation, genetic stability, and clinical use.
DOI: 10.1080/21645515.2018.1513439
PubMed: 30148692
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000797
- to stream PubMed, to step Curation: 000797
- to stream PubMed, to step Checkpoint: 000423
- to stream Ncbi, to step Merge: 001F45
- to stream Ncbi, to step Curation: 001F45
- to stream Ncbi, to step Checkpoint: 001F45
- to stream Main, to step Merge: 000429
- to stream Main, to step Curation: 000426
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Poxviral promoters for improving the immunogenicity of MVA delivered vaccines.</title><author><name sortKey="Alharbi, Naif Khalaf" sort="Alharbi, Naif Khalaf" uniqKey="Alharbi N" first="Naif Khalaf" last="Alharbi">Naif Khalaf Alharbi</name><affiliation wicri:level="1"><nlm:affiliation>a Infectious Disease Research Department , King Abdullah International Medical Research Center (KAIMRC) , Riyadh , Saudi Arabia.</nlm:affiliation><country xml:lang="fr">Arabie saoudite</country><wicri:regionArea>a Infectious Disease Research Department , King Abdullah International Medical Research Center (KAIMRC) , Riyadh </wicri:regionArea><wicri:noRegion>Riyadh </wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2019">2019</date><idno type="RBID">pubmed:30148692</idno><idno type="pmid">30148692</idno><idno type="doi">10.1080/21645515.2018.1513439</idno><idno type="wicri:Area/PubMed/Corpus">000797</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000797</idno><idno type="wicri:Area/PubMed/Curation">000797</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000797</idno><idno type="wicri:Area/PubMed/Checkpoint">000423</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000423</idno><idno type="wicri:Area/Ncbi/Merge">001F45</idno><idno type="wicri:Area/Ncbi/Curation">001F45</idno><idno type="wicri:Area/Ncbi/Checkpoint">001F45</idno><idno type="wicri:Area/Main/Merge">000429</idno><idno type="wicri:Area/Main/Curation">000426</idno><idno type="wicri:Area/Main/Exploration">000426</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Poxviral promoters for improving the immunogenicity of MVA delivered vaccines.</title><author><name sortKey="Alharbi, Naif Khalaf" sort="Alharbi, Naif Khalaf" uniqKey="Alharbi N" first="Naif Khalaf" last="Alharbi">Naif Khalaf Alharbi</name><affiliation wicri:level="1"><nlm:affiliation>a Infectious Disease Research Department , King Abdullah International Medical Research Center (KAIMRC) , Riyadh , Saudi Arabia.</nlm:affiliation><country xml:lang="fr">Arabie saoudite</country><wicri:regionArea>a Infectious Disease Research Department , King Abdullah International Medical Research Center (KAIMRC) , Riyadh </wicri:regionArea><wicri:noRegion>Riyadh </wicri:noRegion></affiliation></author></analytic><series><title level="j">Human vaccines & immunotherapeutics</title><idno type="eISSN">2164-554X</idno><imprint><date when="2019" type="published">2019</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Antibodies, Viral</term><term>Chick Embryo</term><term>Clinical Trials as Topic</term><term>Genetic Vectors</term><term>Humans</term><term>Immunogenicity, Vaccine</term><term>Promoter Regions, Genetic</term><term>Vaccines, Synthetic (immunology)</term><term>Vaccinia virus (genetics)</term><term>Vaccinia virus (immunology)</term><term>Viral Vaccines (genetics)</term><term>Viral Vaccines (immunology)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term><term>Anticorps antiviraux</term><term>Embryon de poulet</term><term>Essais cliniques comme sujet</term><term>Humains</term><term>Immunogénicité des vaccins</term><term>Régions promotrices (génétique)</term><term>Vaccins antiviraux (génétique)</term><term>Vaccins antiviraux (immunologie)</term><term>Vaccins synthétiques (immunologie)</term><term>Vecteurs génétiques</term><term>Virus de la vaccine (génétique)</term><term>Virus de la vaccine (immunologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Viral Vaccines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Vaccines, Synthetic</term><term>Viral Vaccines</term></keywords><keywords scheme="MESH" type="chemical" xml:lang="en"><term>Antibodies, Viral</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Vaccinia virus</term></keywords><keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Vaccins antiviraux</term><term>Virus de la vaccine</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Vaccins antiviraux</term><term>Vaccins synthétiques</term><term>Virus de la vaccine</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Vaccinia virus</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Chick Embryo</term><term>Clinical Trials as Topic</term><term>Genetic Vectors</term><term>Humans</term><term>Immunogenicity, Vaccine</term><term>Promoter Regions, Genetic</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Animaux</term><term>Anticorps antiviraux</term><term>Embryon de poulet</term><term>Essais cliniques comme sujet</term><term>Humains</term><term>Immunogénicité des vaccins</term><term>Régions promotrices (génétique)</term><term>Vecteurs génétiques</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Modified vaccinia virus Ankara (MVA) is a replication-deficient poxvirus, attenuated in chick embryo fibroblast primary cells. It has been utilised as a viral vector to develop many vaccines against cancer and infectious diseases such as malaria, HIV/AIDS, influenza, and tuberculosis, MERS-CoV, and Ebola virus infection. There is accumulating data from many preclinical and clinical studies that highlights the excellent safety and immunogenicity of MVA. However, due to the complex nature of many pathogens and their pathogenicity, MVA vectored vaccine candidates need to be optimised to improve their immunogenicity. One of the main approaches to improve MVA immunogenicity focuses on optimising poxviral promoters that drive recombinant vaccine antigens, encoded within recombinant MVA vector genome. A number of promoters were described or optimised to improve the development of MVA based vaccines such as p7.5, pF11, and mH5 promoters. This review focuses on poxviral promoters, their optimisation, genetic stability, and clinical use.</div></front></TEI><affiliations><list><country><li>Arabie saoudite</li></country></list><tree><country name="Arabie saoudite"><noRegion><name sortKey="Alharbi, Naif Khalaf" sort="Alharbi, Naif Khalaf" uniqKey="Alharbi N" first="Naif Khalaf" last="Alharbi">Naif Khalaf Alharbi</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000426 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000426 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= MersV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:30148692
|texte= Poxviral promoters for improving the immunogenicity of MVA delivered vaccines.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:30148692" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a MersV1
| This area was generated with Dilib version V0.6.33. |  |